NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 132 filers reported holding NOVOCURE LTD in Q1 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $313,358 | -27.4% | 19,403 | +86.6% | 0.00% | -20.0% |
Q2 2023 | $431,600 | -20.3% | 10,400 | +15.6% | 0.01% | -16.7% |
Q1 2023 | $541,260 | -95.5% | 9,000 | -94.5% | 0.01% | -95.2% |
Q4 2022 | $12,058,739 | +11.0% | 164,400 | +15.0% | 0.12% | +6.8% |
Q3 2022 | $10,865,000 | +10.6% | 143,000 | +1.1% | 0.12% | +19.4% |
Q2 2022 | $9,827,000 | -45.0% | 141,400 | -34.4% | 0.10% | -43.7% |
Q1 2022 | $17,862,000 | +8831.0% | 215,600 | +11891.1% | 0.17% | +8600.0% |
Q3 2020 | $200,000 | +1011.1% | 1,798 | +491.4% | 0.00% | – |
Q2 2020 | $18,000 | -94.2% | 304 | -93.4% | 0.00% | -100.0% |
Q1 2020 | $308,000 | -80.3% | 4,580 | -90.8% | 0.00% | -80.0% |
Q2 2018 | $1,565,000 | +43.6% | 50,000 | 0.0% | 0.02% | +42.9% |
Q1 2018 | $1,090,000 | – | 50,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |